Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Not Confirmed
Not Confirmed
28-30 September, 2024
Discovery on TargetDiscovery on Target
Not Confirmed
Not Confirmed
30 September-03 October, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Industry Trade Show
Not Confirmed
28-30 September, 2024
Discovery on TargetDiscovery on Target
Industry Trade Show
Not Confirmed
30 September-03 October, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
25 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/25/2952920/0/en/Avadel-Pharmaceuticals-Announces-Publication-of-Data-Highlighting-Efficacy-of-LUMRYZ-sodium-oxybate-Extended-Release-Oral-Suspension-in-Improving-Narcolepsy-Symptoms-Regardless-of-.html
12 Sep 2024
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/avadel-pharma-says-its-sleep-disorder-drug-remains-under-fda-review-2024-09-12/
03 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/03/2939609/0/en/Avadel-Pharmaceuticals-Announces-Publication-of-RESTORE-Data-Highlighting-Challenges-with-Twice-Nightly-Oxybates-and-Strong-Patient-Preference-for-Once-Nightly-LUMRYZ-Dosing-sodium.html
28 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/28/2936929/0/en/Avadel-Pharmaceuticals-to-Present-at-Upcoming-Investor-Conferences.html
20 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/20/2932758/0/en/Avadel-Pharmaceuticals-Announces-Publication-in-Clinical-Therapeutics-of-Data-Highlighting-Weight-Loss-in-People-with-Narcolepsy-Treated-with-LUMRYZ-sodium-oxybate-Extended-Release.html
08 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/08/2926766/0/en/Avadel-Pharmaceuticals-Provides-Corporate-Update-and-Reports-Second-Quarter-2024-Financial-Results.html
Details:
Lumryz is an investigational, extended-release oral suspension formulation of sodium oxybate being investigated for the treatment of idiopathic hypersomnia.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Brand Name: Lumryz
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2024
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avadel Announces First Patient Dosed in Phase 3 Trial of LUMRYZ for Idiopathic Hypersomnia
Details : Lumryz is an investigational, extended-release oral suspension formulation of sodium oxybate being investigated for the treatment of idiopathic hypersomnia.
Brand Name : Lumryz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 31, 2024
Details:
Lumryz (sodium oxybate) is a once-nightly formulation of the USFDA approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Brand Name: Lumryz
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Sleep
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lumryz (sodium oxybate) is a once-nightly formulation of the USFDA approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Brand Name : Lumryz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 05, 2023
Details:
Lumryz (sodium oxybate) is a once-nightly formulation of the USFDA approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Brand Name: Lumryz
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Sleep
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Rel...
Details : Lumryz (sodium oxybate) is a once-nightly formulation of the USFDA approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Brand Name : Lumryz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 01, 2023
Details:
The offering will be used for obtaining FDA approval of company's lead candidate, Lumryz, an investigational, extended-release formulation of sodium oxybate for the treatment of cataplexy or EDS in adults with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Brand Name: Lumryz
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Jefferies LLC
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 29, 2023
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Jefferies LLC
Deal Size : $125.0 million
Deal Type : Public Offering
Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares
Details : The offering will be used for obtaining FDA approval of company's lead candidate, Lumryz, an investigational, extended-release formulation of sodium oxybate for the treatment of cataplexy or EDS in adults with narcolepsy.
Brand Name : Lumryz
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 29, 2023
Details:
The financing will support the potential commercialization of Lumryz (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Brand Name: Lumryz
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: RTW Investments
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 29, 2023
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : RTW Investments
Deal Size : $75.0 million
Deal Type : Agreement
Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million
Details : The financing will support the potential commercialization of Lumryz (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.
Brand Name : Lumryz
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 29, 2023
Details:
Lumryz (sodium oxybate) is a once-nightly formulation of the approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Brand Name: Lumryz
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lumryz (sodium oxybate) is a once-nightly formulation of the approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Brand Name : Lumryz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 22, 2023
Details:
Lumryz (sodium oxybate) is a sodium salt of GHB, a naturally occurring CNS depressant that increases dopamine levels and increases serotonin turnover. It is being developed for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Brand Name: Lumryz
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2023
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Sleep
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ™ (sodium oxybate) Extended Release...
Details : Lumryz (sodium oxybate) is a sodium salt of GHB, a naturally occurring CNS depressant that increases dopamine levels and increases serotonin turnover. It is being developed for the treatment of cataplexy or excessive daytime sleepiness in adults with nar...
Brand Name : Lumryz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 02, 2023
Details:
Lumryz (sodium oxybate) is a once-nightly formulation of the approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Brand Name: Lumryz
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lumryz (sodium oxybate) is a once-nightly formulation of the approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Brand Name : Lumryz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 24, 2023
Details:
LUMRYZ is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once-at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Brand Name: Lumryz
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2022
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avadel Pharmaceuticals Announces Favorable Ruling on Motion to Delist REMS Patent from FDA’s Ora...
Details : LUMRYZ is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once-at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.
Brand Name : Lumryz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 18, 2022
Details:
LUMRYZ is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of EDS or cataplexy in adults with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Brand Name: Lumryz
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Lead Product(s) : Sodium Oxybate
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LUMRYZ is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of EDS or cataplexy in adults with narcolepsy.
Brand Name : Lumryz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 19, 2022
Excipients
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?